Q-omics provides the consensus-scored PDS5B profile across patient tissues and cancer cell-line models. PDS5B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDS5B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PDS5B protein abundance shows 28,996 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where PDS5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDS5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDS5B survival associations across molecular data types. PDS5B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDS5B RNA expression–survival associations across cancer types. High PDS5B expression shows unfavorable associations in ACC, CESC, BLCA and UVM, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDS5B RNA expression.
This table summarizes PDS5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PDS5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDS5B shows lower tumor expression in KICH, LUAD, THCA and KIRC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher PDS5B RNA expression in tumor versus normal tissue (log2 FC = +0.588, t-test p < 0.001).
This table shows molecular features associated with PDS5B in patient tissues and cancer cell lines. In patient samples, PDS5B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDS5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
